The urinary bladder contains a lining of highly specialized epithelial cells which is known as urothelium or transitional cells. The urothelial cancer develops due to the abnormal growth of urothelium. Urothelial cancer is the most common type of bladder cancer. Urothelial cancer is divided into two types, Invasive and Noninvasive urothelial cancer. In noninvasive urotheliali cancer the inner layers of the urothelial cells are not affected and the tumors can be easily removed. The invasive urothlial cancer affects the inner layer of the bladder which are likely to become metastatic and are hard to treat.
Symptoms of urothelial cancer include blood in urine, pelvic pain, and painful urination. Urothelial cancer is treated through targeted drugs, immunotherapies, chemotherapies and radiation. The tumors are also through various surgical procedures.
Global Urothelial Cancer Treatment Market – Dynamics
Rising incidences of bladder cancer is expected to propel growth of the global urothelial cancer treatment market over the forecast period. For instance, on May 2019, according to the American Society of Clinical Oncology (ASCO), May 2019, urolthelial cancer makes up about 90% of all the bladder cancers.
Moreover, increasing number of new bladder cancer cases is also anticipated to drive the growth of the market during the forecasted period. For instance, according to the World Cancer Research Fund, nearly 550,000 new cases of bladder cancer were reported worldwide in 2018.
Major players are adopting expansion strategies to further strengthen their market position through mergers, agreements and acquisitions which is expected to drive the urothellial cancer treatment market over the forecast period. For instance, in December 2019, Seattle Genetics, Inc. and Astellas Pharma Inc. entered into a collaboration with Merck & Co., Inc., to initiate a phase 3 clinical trial to evaluate enfortumab vedotin and KEYTRUDA for the treatment of metastatic urothelial cancer.
Global Urothelial Cancer Treatment Market – Regional Insights
North America accounted for the largest market share in 2018. This is attributed to rising incidences of bladder cancers in the region. For instance, in January 2020, the American Cancer Society estimated that, approximately 81,400 people are expected to get diagnosed with bladder cancer in the U.S in year 2020.
Moreover, key players are focusing on enhancing their product portfolio through product launches and new product approvals for urothelial cancer treatment, which is expected to boost urothelial cancer treatment market growth over the forecast period in the region. For instance, in February 2017, Bristol-Myers Squibb Company received the U.S Food and Drug Administration approval for Opdivo, an injection developed for the patients with metastatic locally or advanced urothelial carcinoma.
Europe is expected to be the second-largest market for global urothelial cancer treatment market and it is projected to witness significant growth over the forecast period, owing to increasing cases of bladder cancer in the region. For instance, according to the Cancer Research UK, approximately 10,187 new cases of bladder cancer were registered from 2014 to 2016 in the UK.
Global Urothelial Cancer Treatment Market – Competitive Landscape
Key players operating in the urothelial cancer treatment market include Johnson & Johnson, Bristol-Myers Squibb Company, Genentech, Inc., Novartis International AG, Sanofi S.A., Eisai Co., Ltd., Seattle Genetics, Inc., Astellas Pharma Inc., and Merck & Co., Inc.
Global Urothelial Cancer Treatment Market – Taxonomy
On the basis of urothelial cancer type, global urothelial cancer treatment market is segmented into:
On the basis of treatment type, global urothelial cancer treatment market is segmented into:
On the basis of distribution channel, global urothelial cancer treatment market is segmented into:
On the basis of region, global urothelial cancer treatment market is segmented into: